newsfilter
← Latest News
GlobeNewswire·

Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings

AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF mutation-positive (BRAF+) solid tumors ASCO GI Cancer